GRAIL, Inc. Common Stock (GRAL) — Analysis Summary
GRAIL, Inc. Common Stock (GRAL) has a market cap of $6.14B with year-over-year revenue growth of +17.2%. Net margin stands at -277.5%. The stock trades at a P/E ratio of -15.7.
Key Takeaways
- Revenue changed +17.2% year-over-year
- Net margin of -277.5%
- P/E ratio of -15.7
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, GRAL posted revenue growth of +17.2% and trades at a P/E of -15.7.
GRAIL, Inc. Common Stock (GRAL)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -338.4% — severe operating losses
Net margin at -236.9% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Sector
SERVICES-MEDICAL LABORATORIES
Employees
910
Headquarters
MENLO PARK, CA
Exchange
XNAS
At least 3 years of annual financial data required to assess competitive moat.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.